|
Gene: CMAS |
Gene summary for CMAS |
Gene summary. |
Gene information | Species | Human | Gene symbol | CMAS | Gene ID | 55907 |
Gene name | cytidine monophosphate N-acetylneuraminic acid synthetase | |
Gene Alias | CSS | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006040 | UniProtAcc | Q8NFW8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55907 | CMAS | HTA11_78_2000001011 | Human | Colorectum | AD | 2.40e-02 | 4.86e-01 | -0.1088 |
55907 | CMAS | HTA11_347_2000001011 | Human | Colorectum | AD | 1.08e-17 | 8.15e-01 | -0.1954 |
55907 | CMAS | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.12e-13 | 7.25e-01 | 0.294 |
55907 | CMAS | A015-C-203 | Human | Colorectum | FAP | 1.58e-04 | -1.60e-01 | -0.1294 |
55907 | CMAS | A015-C-204 | Human | Colorectum | FAP | 9.76e-04 | -2.17e-01 | -0.0228 |
55907 | CMAS | A002-C-201 | Human | Colorectum | FAP | 6.60e-06 | -1.42e-01 | 0.0324 |
55907 | CMAS | A001-C-119 | Human | Colorectum | FAP | 3.74e-05 | -3.01e-01 | -0.1557 |
55907 | CMAS | A001-C-108 | Human | Colorectum | FAP | 4.45e-02 | -1.54e-01 | -0.0272 |
55907 | CMAS | A002-C-205 | Human | Colorectum | FAP | 8.27e-12 | -2.93e-01 | -0.1236 |
55907 | CMAS | A015-C-005 | Human | Colorectum | FAP | 1.14e-04 | -2.26e-01 | -0.0336 |
55907 | CMAS | A015-C-006 | Human | Colorectum | FAP | 1.93e-04 | -1.63e-01 | -0.0994 |
55907 | CMAS | A015-C-106 | Human | Colorectum | FAP | 2.29e-02 | -1.54e-01 | -0.0511 |
55907 | CMAS | A002-C-114 | Human | Colorectum | FAP | 9.69e-07 | -1.34e-01 | -0.1561 |
55907 | CMAS | A015-C-104 | Human | Colorectum | FAP | 9.97e-07 | -2.30e-01 | -0.1899 |
55907 | CMAS | A001-C-014 | Human | Colorectum | FAP | 2.06e-02 | -1.80e-01 | 0.0135 |
55907 | CMAS | A002-C-016 | Human | Colorectum | FAP | 2.71e-05 | -1.66e-01 | 0.0521 |
55907 | CMAS | A015-C-002 | Human | Colorectum | FAP | 2.23e-04 | -2.14e-01 | -0.0763 |
55907 | CMAS | A001-C-203 | Human | Colorectum | FAP | 4.75e-02 | -1.45e-01 | -0.0481 |
55907 | CMAS | A002-C-116 | Human | Colorectum | FAP | 2.65e-06 | -1.68e-01 | -0.0452 |
55907 | CMAS | A014-C-008 | Human | Colorectum | FAP | 5.93e-05 | -2.34e-01 | -0.191 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006040 | Oral cavity | OSCC | amino sugar metabolic process | 24/7305 | 42/18723 | 1.30e-02 | 4.34e-02 | 24 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01250 | Colorectum | FAP | Biosynthesis of nucleotide sugars | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
hsa012501 | Colorectum | FAP | Biosynthesis of nucleotide sugars | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
hsa012502 | Colorectum | CRC | Biosynthesis of nucleotide sugars | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
hsa012503 | Colorectum | CRC | Biosynthesis of nucleotide sugars | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CMAS | SNV | Missense_Mutation | novel | c.1207T>C | p.Tyr403His | p.Y403H | Q8NFW8 | protein_coding | deleterious(0) | possibly_damaging(0.633) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CMAS | SNV | Missense_Mutation | rs777453073 | c.601N>T | p.Arg201Trp | p.R201W | Q8NFW8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CMAS | SNV | Missense_Mutation | novel | c.562N>T | p.Arg188Cys | p.R188C | Q8NFW8 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CMAS | SNV | Missense_Mutation | novel | c.469N>A | p.Val157Ile | p.V157I | Q8NFW8 | protein_coding | deleterious(0.01) | benign(0.438) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CMAS | SNV | Missense_Mutation | novel | c.510N>A | p.Phe170Leu | p.F170L | Q8NFW8 | protein_coding | tolerated(0.17) | probably_damaging(0.934) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CMAS | SNV | Missense_Mutation | novel | c.540N>T | p.Trp180Cys | p.W180C | Q8NFW8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CMAS | deletion | Frame_Shift_Del | c.697delN | p.Gly233GlufsTer16 | p.G233Efs*16 | Q8NFW8 | protein_coding | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |||
CMAS | SNV | Missense_Mutation | c.913N>T | p.Val305Leu | p.V305L | Q8NFW8 | protein_coding | tolerated(0.66) | benign(0) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CMAS | SNV | Missense_Mutation | novel | c.1033N>A | p.Val345Ile | p.V345I | Q8NFW8 | protein_coding | tolerated(0.43) | benign(0) | TCGA-50-6592-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CMAS | SNV | Missense_Mutation | novel | c.557N>T | p.Gly186Val | p.G186V | Q8NFW8 | protein_coding | deleterious(0.01) | possibly_damaging(0.89) | TCGA-55-7576-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |